Zirconium-labeled monoclonal antibodies and their distribution in tumor- bearing nude mice

Journal of Nuclear Medicine

Volumn 38, Issue 1, 1997, Pages 112-118

  Meijs, Wilma E ^b   Haisma, Hidde J ^b   Klok, Rob P ^b   Van Gog, Frank B ^b   Kievit, Els ^b   Pinedo, Herbert M ^b   Herscheid, Jacobus D M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b NONE

Author keywords

antibody labeling; desferal; PET; zirconium 88; zirconium 89

Indexed keywords

CHELATING AGENT; DEFEROXAMINE MESYLATE; MONOCLONAL ANTIBODY; ZIRCONIUM;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RETENTION; DRUG STABILITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; DEFEROXAMINE; IMMUNOCONJUGATES; ISOTOPE LABELING; MICE; MICE, NUDE; NEOPLASMS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; ZIRCONIUM;

EID: 0031013070     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Eary JF. Fundamentals of radioimmunotherapy. Nucl Med Biol 1991; 18:105-108.
2. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993;20:551-567.
3. Larson SM, Divgi CR, Scott A, et al. Current status of radioimmunotherapy. Nucl Med Biol 1994;21:785-792.
4. Leichner PK, Kwok CS. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles. Med Phys 1993;20:529-534.
5. Sorensen JA, Phelps ME. Nuclear medicine tomography: systems and devices. In: Sorensen JA and Phelps ME, eds. Physics in nuclear medicine, 2nd edition. Philadelphia, PA: W.B. Saunders; 1987:424-451.
6. 111In-labeled monoclonal antibodies. Nucl Med Biol 1986;13:325-334.
7. Khaw BA, Cooney J, Edgington T, Strauss HW. Differences in experimental tumor localization of dual-labeled monoclonal antibody. J Nucl Med 1986;27:1293-1299.
8. Ryser JE, Jones RML, Egeli R, et al. Colon carcinoma immunoscintigraphy by monoclonal anti-CEA antibody labeled with gallium-67-aminooxyacetyldeferroxamine. J Nucl Med 1992;33:1766-1773.
9. 89Zr, a potential PET antibody label. Appl Radiat Isot 1990;41:789-790.
10. Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emmission tomography. Appl Radiat Isot 1991;42:199-201.
11. 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isot 1994;45:1143-1147.
12. Mealey J. Turn-over of carrier-free zirconium-89 in man. Nature 1957;179:673-674.
13. Fletcher CR. The radiological hazards of zirconium-95 and niobium-95. Health Physics 1969;16:209-220.
14. 95Nb in new-born, juvenile and adult rats. Health Physics 1972;22:373-378.
15. Baroncelli F, Grossi G. The complexing power of hydroxamic acids and its effect on the behaviour of organic extradants in the reprocessing of irradiated fuels-I. The complexes between benzohydroxamic acid and zirconium, iron(III) and uranium(VI). J Inorg Nucl Chem 1965;27:1085-1092.
16. Meijs WE, Herscheid JDM, Haisma HJ, Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isot 1992;43:1443-1447.
17. Jiménez CR, van Veelen PA, Li KW, et al. Neuropeptide expression and processing as revealed by direct matrix-assisted laser desorption ionization mass spectrometry of single neurons. J Neurochem 1994;62:404-407.
18. r 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 1986;46:1306-1317.
19. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GAMS. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targeting tumours in the upper aerodigestive and respiratory tract. Nucl Med Commun 1994;15:613-627.
20. Quak JJ, Balm AJM, van Dongen GAMS, et al. A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am J Path 1990;136:191-197.
21. 2. Cancer Res 1992;52:2569-2574.
22. 2. J Nucl Med 1994;35:775-783.
23. Visser GWM, Gerretsen M, Herscheid JDM, Snow GB, van Dongen G. Labeling of monoclonal antibodies with Rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-1963.
24. Haisma HJ, Hilgers J, Zurawski VR, Jr. Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one-vial method. J Nucl Med 1986;27: 1890-1895.
25. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-5389.
26. Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJF, Pinedo HM. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 1992;66:474-478.
27. Brakenhof RH, Gerretsen M, Knippels EMC, et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 1995;129:1677-1689.
28. Carey TE. Establishment of epidermoid carcinoma cell lines. In: Wittes RE, eds. Head and neck cancer. New York, NY: John Wiley and Sons; 1995:287-314.
29. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Method 1984;72:77-89.
30. Paans AMJ, Tilkema SP, Pruim J, et al. Performance parameters of the Siemens 95 ECAT positron camera with its new computer configuration [Abstract]. Eur J Nucl Med 1991;18:603.
31. Pak KY, Nedelman MA, Kanke M, et al. An instant kit method for labeling antimyosin Fab′ with technetium-99m: evaluation in an experimental myocardial infarct model. J Nucl Med 1992;33:144-149.
32. 99mTc-labeling method. Nucl Med Biol 1992;19:669-677.
33. 67Ga-labeled urokinase. Int J Nucl Med Biol 1985;12:47-52.
34. 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate. An improved method. J Immunol Methods 1987;104:93-102.
35. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Nucl Med Biol 1991;18:389-394.
36. 67Cu-labeled intact and fragmentated anti-colon carcinoma monoclonal antibody MAb35. Cancer Res 1993;53:5727-5733.
37. Desphande SV, Subramanian R, McCall MJ, DeNardo SJ, DeNardo GL, Meares CF. Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. J Nucl Med 1990;31:218-224.
38. Motta-Hennessy C, Sharkey RM, Goldenberg DM. Metabolsim of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 1990;31:1510-1519.
39. Studer M, Kroger LA, DeNardo SJ, Kukis DL, Meares CF. Influence of a peptide linker on biodistribution and metabolism of antibody-conjugates benzyl-EDTA. Comparison of enzymatic digestion in vitro en vivo. Bioconjugate Chem 1992;3:424-429.
40. 125I radiolabeled T101 anti-CD5 monoclonal antibody. Nucl Med Biol 1990;17:201-207.
41. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA labeled receptor targeted proteins. J Nucl Med 1993;34:1728-1738.
42. 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice. Cancer Res 1989;49:1752-1757.
43. ICRP Publication 30, part 1. Limits for intakes of radionuclides by workers. Ann ICRP 1979;2:88-90.
44. ICRP Publication 30, part 2. Statement and recommendations of the 1980 Brighton meeting of the ICRP. Limits for intakes of radionuclides by workers. Ann ICRP 1980;4:32-34.
45. 75Se-labeled monoclonal antibody. Biodistribution in tumour-bearing nude mice. Nucl Med Biol 1994;21:1017-1021.